FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793082912> ?p ?o ?g. }

• W2793082912 endingPage "107" @default.
• W2793082912 startingPage "96" @default.
• W2793082912 abstract "Background Hospital readmissions are associated not only with increased mortality, morbidity, and costs but also, with current health-care reform, tied to significant financial and administrative penalties. Some studies show that patients undergoing vascular surgery may have higher than average readmission rates. The recently released Nationwide Readmission Database (NRD) is the most comprehensive national source of readmission data, gathering discharge information from 22 geographically dispersed states, accounting for 51.2% of the total U.S. resident population and 49.3% of all U.S. hospitalizations. The aim of this study is to use the power of the NRD and obtain nationally representative readmission information for patients admitted with claudication or critical limb ischemia (CLI) who underwent revascularization procedures. Methods The NRD was queried for all patients admitted for claudication (International Classification of Diseases Ninth Revision [ICD-9] 440.21) or CLI (ICD-9 440.22–440.24) and who underwent percutaneous transluminal angioplasty, peripheral bypass, or aortofemoral bypass. Patient demographics, comorbidities, length of stay (LOS), mortality, readmission rates, and associated costs were collected. Univariable and multivariable logistic regression analysis was implemented on claudication and CLI groups on all outcomes of interest. The most common readmission diagnosis codes and diagnosis groups were also identified. Results A total of 92,769 patients were admitted for peripheral vascular disease (33,055 with claudication and 59,714 with CLI). The 30-day readmission/any readmission rate was 8.97%/21.49% and 19.26%/40.36%, for claudication and CLI, respectively. Significant differences were found for claudication and CLI, respectively, on initial cost of admission ($18,548 vs. $29,148, P < 0.001), readmission costs ($14,726 vs. $17,681 P < 0.001), LOS (4 days vs. 9 days, P < 0.001), days to readmission (73 days vs. 59 days, P < 0.001), mortality during initial admission (256 vs. 1,363, P < 0.001), and mortality during any admission (538 vs. 3,838, P < 0.001). Univariate and multivariate logistic regression analysis found that claudication, CLI, angioplasty, peripheral bypass, aortofemoral bypass, female sex, age >65, Charlson Comorbidity Index, LOS, and primary expected payer status were all significant predictors of 30-day and overall readmissions at varying degrees. The 5 most common disease readmission groups found were other vascular procedures (12.6%), amputation of lower limb except toes (6.3%), sepsis (5.4%), heart failure (4.9%) and postoperative or other device infections (4.8%). Of the abovementioned groups, the 4 most common diagnoses included “other postoperative infections,” sepsis, atherosclerosis of native arteries with gangrene, and “other complications due to other vascular device, implant, or graft.” Conclusions Our results demonstrate that there is a significant difference in readmission rates, cost, and morbidity between patients admitted for claudication and CLI. Furthermore, based on regression analysis, there are multiple other clear risk factors associated with worse clinical and economic outcomes. Further study is needed to predict which patients will require increased vigilance during their hospital stay to prevent readmissions and worse outcomes. Level of Evidence Care management/epidemiological, level IV. Hospital readmissions are associated not only with increased mortality, morbidity, and costs but also, with current health-care reform, tied to significant financial and administrative penalties. Some studies show that patients undergoing vascular surgery may have higher than average readmission rates. The recently released Nationwide Readmission Database (NRD) is the most comprehensive national source of readmission data, gathering discharge information from 22 geographically dispersed states, accounting for 51.2% of the total U.S. resident population and 49.3% of all U.S. hospitalizations. The aim of this study is to use the power of the NRD and obtain nationally representative readmission information for patients admitted with claudication or critical limb ischemia (CLI) who underwent revascularization procedures. The NRD was queried for all patients admitted for claudication (International Classification of Diseases Ninth Revision [ICD-9] 440.21) or CLI (ICD-9 440.22–440.24) and who underwent percutaneous transluminal angioplasty, peripheral bypass, or aortofemoral bypass. Patient demographics, comorbidities, length of stay (LOS), mortality, readmission rates, and associated costs were collected. Univariable and multivariable logistic regression analysis was implemented on claudication and CLI groups on all outcomes of interest. The most common readmission diagnosis codes and diagnosis groups were also identified. A total of 92,769 patients were admitted for peripheral vascular disease (33,055 with claudication and 59,714 with CLI). The 30-day readmission/any readmission rate was 8.97%/21.49% and 19.26%/40.36%, for claudication and CLI, respectively. Significant differences were found for claudication and CLI, respectively, on initial cost of admission ($18,548 vs. $29,148, P < 0.001), readmission costs ($14,726 vs. $17,681 P < 0.001), LOS (4 days vs. 9 days, P < 0.001), days to readmission (73 days vs. 59 days, P < 0.001), mortality during initial admission (256 vs. 1,363, P < 0.001), and mortality during any admission (538 vs. 3,838, P < 0.001). Univariate and multivariate logistic regression analysis found that claudication, CLI, angioplasty, peripheral bypass, aortofemoral bypass, female sex, age >65, Charlson Comorbidity Index, LOS, and primary expected payer status were all significant predictors of 30-day and overall readmissions at varying degrees. The 5 most common disease readmission groups found were other vascular procedures (12.6%), amputation of lower limb except toes (6.3%), sepsis (5.4%), heart failure (4.9%) and postoperative or other device infections (4.8%). Of the abovementioned groups, the 4 most common diagnoses included “other postoperative infections,” sepsis, atherosclerosis of native arteries with gangrene, and “other complications due to other vascular device, implant, or graft.” Our results demonstrate that there is a significant difference in readmission rates, cost, and morbidity between patients admitted for claudication and CLI. Furthermore, based on regression analysis, there are multiple other clear risk factors associated with worse clinical and economic outcomes. Further study is needed to predict which patients will require increased vigilance during their hospital stay to prevent readmissions and worse outcomes." @default.
• W2793082912 created "2018-03-29" @default.
• W2793082912 creator A5022535713 @default.
• W2793082912 creator A5023569425 @default.
• W2793082912 creator A5034890117 @default.
• W2793082912 creator A5040505164 @default.
• W2793082912 creator A5041648323 @default.
• W2793082912 creator A5051900366 @default.
• W2793082912 creator A5061004920 @default.
• W2793082912 creator A5063337603 @default.
• W2793082912 date "2018-10-01" @default.
• W2793082912 modified "2023-10-01" @default.
• W2793082912 title "Nationally Representative Readmission Factors in Patients with Claudication and Critical Limb Ischemia" @default.
• W2793082912 cites W1975817724 @default.
• W2793082912 cites W2000445173 @default.
• W2793082912 cites W2011966376 @default.
• W2793082912 cites W2084679456 @default.
• W2793082912 cites W2113135476 @default.
• W2793082912 cites W2141159107 @default.
• W2793082912 cites W2154397902 @default.
• W2793082912 cites W2163228796 @default.
• W2793082912 cites W2170131723 @default.
• W2793082912 cites W2210402696 @default.
• W2793082912 cites W2276880546 @default.
• W2793082912 cites W2334580318 @default.
• W2793082912 cites W2344791925 @default.
• W2793082912 cites W2401249553 @default.
• W2793082912 cites W2515956471 @default.
• W2793082912 cites W2516954888 @default.
• W2793082912 cites W2571674534 @default.
• W2793082912 cites W2587493640 @default.
• W2793082912 cites W2612176626 @default.
• W2793082912 cites W2755883860 @default.
• W2793082912 doi "https://doi.org/10.1016/j.avsg.2018.03.011" @default.
• W2793082912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29777842" @default.
• W2793082912 hasPublicationYear "2018" @default.
• W2793082912 type Work @default.
• W2793082912 sameAs 2793082912 @default.
• W2793082912 citedByCount "19" @default.
• W2793082912 countsByYear W27930829122018 @default.
• W2793082912 countsByYear W27930829122019 @default.
• W2793082912 countsByYear W27930829122020 @default.
• W2793082912 countsByYear W27930829122021 @default.
• W2793082912 countsByYear W27930829122022 @default.
• W2793082912 countsByYear W27930829122023 @default.
• W2793082912 crossrefType "journal-article" @default.
• W2793082912 hasAuthorship W2793082912A5022535713 @default.
• W2793082912 hasAuthorship W2793082912A5023569425 @default.
• W2793082912 hasAuthorship W2793082912A5034890117 @default.
• W2793082912 hasAuthorship W2793082912A5040505164 @default.
• W2793082912 hasAuthorship W2793082912A5041648323 @default.
• W2793082912 hasAuthorship W2793082912A5051900366 @default.
• W2793082912 hasAuthorship W2793082912A5061004920 @default.
• W2793082912 hasAuthorship W2793082912A5063337603 @default.
• W2793082912 hasConcept C126322002 @default.
• W2793082912 hasConcept C141071460 @default.
• W2793082912 hasConcept C151956035 @default.
• W2793082912 hasConcept C160735492 @default.
• W2793082912 hasConcept C162324750 @default.
• W2793082912 hasConcept C1862650 @default.
• W2793082912 hasConcept C194828623 @default.
• W2793082912 hasConcept C2777010666 @default.
• W2793082912 hasConcept C2777466421 @default.
• W2793082912 hasConcept C2778789114 @default.
• W2793082912 hasConcept C2778963770 @default.
• W2793082912 hasConcept C2779195980 @default.
• W2793082912 hasConcept C2779464278 @default.
• W2793082912 hasConcept C2779881954 @default.
• W2793082912 hasConcept C2781099653 @default.
• W2793082912 hasConcept C2908647359 @default.
• W2793082912 hasConcept C3018348675 @default.
• W2793082912 hasConcept C45827449 @default.
• W2793082912 hasConcept C500558357 @default.
• W2793082912 hasConcept C50522688 @default.
• W2793082912 hasConcept C71924100 @default.
• W2793082912 hasConcept C99454951 @default.
• W2793082912 hasConceptScore W2793082912C126322002 @default.
• W2793082912 hasConceptScore W2793082912C141071460 @default.
• W2793082912 hasConceptScore W2793082912C151956035 @default.
• W2793082912 hasConceptScore W2793082912C160735492 @default.
• W2793082912 hasConceptScore W2793082912C162324750 @default.
• W2793082912 hasConceptScore W2793082912C1862650 @default.
• W2793082912 hasConceptScore W2793082912C194828623 @default.
• W2793082912 hasConceptScore W2793082912C2777010666 @default.
• W2793082912 hasConceptScore W2793082912C2777466421 @default.
• W2793082912 hasConceptScore W2793082912C2778789114 @default.
• W2793082912 hasConceptScore W2793082912C2778963770 @default.
• W2793082912 hasConceptScore W2793082912C2779195980 @default.
• W2793082912 hasConceptScore W2793082912C2779464278 @default.
• W2793082912 hasConceptScore W2793082912C2779881954 @default.
• W2793082912 hasConceptScore W2793082912C2781099653 @default.
• W2793082912 hasConceptScore W2793082912C2908647359 @default.
• W2793082912 hasConceptScore W2793082912C3018348675 @default.
• W2793082912 hasConceptScore W2793082912C45827449 @default.
• W2793082912 hasConceptScore W2793082912C500558357 @default.
• W2793082912 hasConceptScore W2793082912C50522688 @default.
• W2793082912 hasConceptScore W2793082912C71924100 @default.
• W2793082912 hasConceptScore W2793082912C99454951 @default.

• next